Effect of Levodopa‐carbidopa Intestinal Gel on Non‐motor Symptoms in Patients with Advanced Parkinson's Disease

BACKGROUND: Levodopa‐carbidopa intestinal gel (LCIG; carbidopa‐levodopa enteral suspension in the United States), delivered via percutaneous gastrojejunostomy (PEG‐J) and titrated in the inpatient setting, is an established treatment option for advanced Parkinson's disease (PD) patients with mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Standaert, David G., Rodriguez, Ramon L., Slevin, John T., Lobatz, Michael, Eaton, Susan, Chatamra, Krai, Facheris, Maurizio F., Hall, Coleen, Sail, Kavita, Jalundhwala, Yash J., Benesh, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724683/
https://www.ncbi.nlm.nih.gov/pubmed/29242809
http://dx.doi.org/10.1002/mdc3.12526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724683/
https://www.ncbi.nlm.nih.gov/pubmed/29242809
http://dx.doi.org/10.1002/mdc3.12526

Ejemplares similares